To include your compound in the COVID-19 Resource Center, submit it here.

DC Vaccine containing WT1/PRAME: Phase I/II started

Medigene began an open-label, Norwegian Phase I/II trial to evaluate its DC Vaccine containing WT1/PRAME

Read the full 157 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE